Please login to the form below

Not currently logged in
Email:
Password:

Zurampic

This page shows the latest Zurampic news and features for those working in and with pharma, biotech and healthcare.

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug

Ironwood bought rights to Duzallo (allopurinol and lesinurad) and single-agent Zurampic (lesinurad) from AstraZeneca last year in a $265m deal, including $100m upfront, which came amid a massive slimming down ... The approval of Duzallo was based on the

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both

  • Deal Watch June 2016 Deal Watch June 2016

    As part of the transaction Grünenthal has the option to take over manufacturing of Zurampic from AstraZeneca from October 2021. ... licence. 270. AstraZeneca/ Grünenthal. Zurampic (lesinurad) and lesinurad fixed-dose combo with allopurinol for

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... Annual US sales of Zurampic are estimated by Ironwood at

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics